Metipranolol Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Metipranolol
Therapeutic Class: Beta-adrenergic blocker (ophthalmic)
Subclass: Non-selective beta-blocker (topical)
Speciality: Ophthalmology
Schedule (India): Schedule H
Route(s): Ophthalmic (topical only)
Formulations Available in India:
| Formulation | Strength | Pack Size |
| Eye drops | 0.3% | 5 mL bottle |
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
⮞ Ocular Hypertension / Primary Open-Angle Glaucoma
| Parameter | Recommendation |
| Starting dose | 1 drop of 0.3% solution twice daily in affected eye(s) |
| Titration | Not usually required; assess IOP after 2–4 weeks |
| Usual maintenance dose | 1 drop twice daily |
| Maximum dose | 1 drop twice daily (higher frequency not shown to improve efficacy) |
Clinical Notes:
- May be used as monotherapy or in combination with other anti-glaucoma agents (carbonic anhydrase inhibitors, prostaglandin analogues)
- Onset of IOP-lowering effect: within 30 minutes
- Peak effect: 2–3 hours post-instillation
- Instruct patient to apply nasolacrimal occlusion for 1–2 minutes after instillation to minimise systemic absorption
Secondary Indications — Adults Only (Off-label, if any)
Not commonly used for other indications in Indian clinical practice.
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
NOT RECOMMENDED in children under 12 years due to limited safety data and risk of systemic beta-blockade effects.
Secondary Indications — Paediatric Doses (Off-label, if any)
⮞ Paediatric Glaucoma (e.g., Juvenile Open-Angle Glaucoma) — OFF-LABEL
| Parameter | Recommendation |
| Age | ≥5 years (avoid below 5 years unless absolutely necessary) |
| Dose | 1 drop of 0.3% in affected eye(s) once or twice daily |
| Maximum | 2 drops/day per eye |
| Supervision | Paediatric ophthalmologist only |
Safety Monitoring:
- Heart rate and rhythm (risk of bradycardia)
- Respiratory status (bronchospasm risk, especially in children <5 years)
- Growth and feeding patterns
- Blood pressure monitoring
Evidence basis: Limited paediatric data; extrapolated from adult studies and specialist practice protocols
Statement: Not recommended below 5 years of age except under specialist supervision with documented failure of alternative agents.
RENAL ADJUSTMENT
| Renal Status | Recommendation |
| All stages (including ESRD) | No dosage adjustment required |
Rationale: Minimal systemic absorption following ophthalmic administration; negligible renal excretion of absorbed fraction.
HEPATIC ADJUSTMENT
| Severity | Recommendation |
| Mild impairment | No adjustment required |
| Moderate impairment | No specific adjustment; monitor for systemic effects |
| Severe impairment | Use with caution; risk of systemic beta-blockade if absorption occurs; close cardiovascular monitoring advised |
CONTRAINDICATIONS
- Hypersensitivity to metipranolol, other beta-blockers, or any excipients
- Sinus bradycardia (<50 bpm)
- Second or third-degree atrioventricular block (unless permanent pacemaker in situ)
- Uncontrolled or decompensated cardiac failure
- Cardiogenic shock
- Bronchial asthma (current or history)
- Severe chronic obstructive pulmonary disease with bronchospastic component
- Sick sinus syndrome
CAUTIONS
- Mild to moderate COPD without bronchospastic component — monitor respiratory function
- Diabetes mellitus — may mask adrenergic symptoms of hypoglycaemia (tremor, tachycardia)
- Thyrotoxicosis — may mask symptoms of thyroid storm
- Myasthenia gravis — potential worsening of muscle weakness
- Concurrent use of systemic beta-blockers — additive systemic effects
- Peripheral vascular disease — may exacerbate symptoms
- History of severe anaphylaxis — may diminish response to epinephrine
- Corneal disease — benzalkonium chloride preservative may worsen epithelial toxicity
- Prior to intraocular surgery — consider discontinuation if feasible
PREGNANCY
| Parameter | Details |
| Safety category | Limited human data; avoid unless clearly necessary |
| Risk | Beta-blockers may cause fetal bradycardia, hypoglycaemia, and growth restriction |
| Preferred alternatives | Brimonidine (after first trimester), latanoprost — with obstetric input |
| When permissible | Only when IOP control is essential and alternatives unsuitable; involve maternal-fetal medicine specialist |
| Monitoring | Fetal heart rate monitoring if used in third trimester; neonatal observation for 48–72 hours post-delivery |
LACTATION
| Parameter | Details |
| Compatibility | Likely compatible with breastfeeding when nasolacrimal occlusion technique used |
| Drug levels in milk | Expected to be very low due to minimal systemic absorption |
| Preferred alternatives | Timolol ophthalmic (more safety data in lactation) |
| Infant monitoring | Observe for bradycardia, poor feeding, lethargy, respiratory depression |
ELDERLY
| Parameter | Recommendation |
| Starting dose | No dose modification required |
| Titration | Cautious if concurrent systemic beta-blocker or cardiovascular medications |
| Special risks | Bradycardia, orthostatic hypotension, confusion, depression (rare but reported with systemic absorption) |
| Monitoring | Heart rate, blood pressure, cognitive function in long-term users |
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
| Systemic beta-blockers (propranolol, atenolol, metoprolol) | Additive bradycardia, hypotension, heart block | Avoid combination or monitor HR and BP closely |
| Verapamil, diltiazem (systemic) | Increased risk of AV block, bradycardia, cardiac depression | Avoid; if essential, cardiac monitoring required |
| Digitalis glycosides (digoxin) | Additive bradycardia, AV conduction delay | Monitor heart rate; consider ECG surveillance |
| Class I antiarrhythmics (quinidine, flecainide) | Additive negative inotropic and dromotropic effects | Avoid concurrent use |
| Amiodarone | Profound bradycardia, hypotension | Avoid combination |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
| Clonidine | Rebound hypertension if clonidine discontinued abruptly | Discontinue beta-blocker several days before tapering clonidine |
| Insulin, sulfonylureas | Masking of hypoglycaemia warning symptoms | Educate patient; frequent blood glucose monitoring |
| CYP2D6 inhibitors (fluoxetine, paroxetine) | Potential for increased systemic beta-blocker effect | Monitor for bradycardia |
| Other topical ophthalmic agents | Dilution effect, altered absorption | Allow 5–10 minutes between different eye drops |
| NSAIDs | May reduce antihypertensive effect if systemic absorption occurs | Clinical significance low for topical beta-blockers |
COMMON ADVERSE EFFECTS
- Transient ocular stinging or burning upon instillation
- Blurred vision (temporary)
- Conjunctival hyperaemia
- Foreign body sensation
- Dry eyes
- Tearing or lacrimation
- Blepharitis
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Clinical Action |
| Symptomatic bradycardia, AV block | Discontinue immediately; cardiology referral |
| Bronchospasm, asthma exacerbation | Stop drug; manage with bronchodilators; avoid rechallenge |
| Severe hypotension | Discontinue; supportive care |
| Stevens-Johnson syndrome/TEN (very rare) | Immediate discontinuation; dermatology and ICU referral |
| Severe allergic conjunctivitis or periorbital oedema | Discontinue; switch to alternative class |
| Depression, confusion (especially elderly) | Consider discontinuation; psychiatric evaluation if severe |
MONITORING REQUIREMENTS
| Phase | Parameters |
| Baseline | Intraocular pressure (IOP), heart rate, blood pressure, respiratory assessment |
| After initiation | Recheck IOP at 2–4 weeks; HR weekly if on concomitant systemic beta-blocker |
| Long-term | IOP every 3–6 months; annual fundoscopy and visual field assessment; monitor for ocular surface toxicity (especially if using preserved formulation) |
BRANDS AVAILABLE IN INDIA
| Brand Name | Manufacturer | Strength |
| Optipranolol Eye Drops | Bausch + Lomb | 0.3% (5 mL) |
Note: Limited brand availability in India; may require procurement through specific distributors.
PRICE RANGE (INR)
| Parameter | Details |
| Approximate cost | ₹50–100 per 5 mL bottle |
| NLEM status | Not included under NLEM |
| Availability | Primarily private ophthalmic practice; limited hospital formulary inclusion |
CLINICAL PEARLS
- Alternative agent: Less commonly prescribed than timolol; consider when patient shows intolerance or inadequate response to timolol
- Nasolacrimal occlusion technique: Always instruct patients to press inner canthus for 1–2 minutes post-instillation to reduce systemic absorption
- Asthma precaution: Avoid even topical use in asthmatics — bronchospasm reported with ophthalmic beta-blockers
- Combination therapy: Can be combined with prostaglandin analogues or carbonic anhydrase inhibitors for additive IOP reduction
- Elderly monitoring: Watch for subtle mood changes, fatigue, or depression on chronic use
- Preservative sensitivity: For patients with ocular surface disease, preservative-free alternatives (if available) or switch to another class may be preferable
TAGS
metipranolol; glaucoma; ocular hypertension; beta-blocker; ophthalmic; non-selective; asthma-contraindicated; elderly-use; pregnancy-caution; ophthalmology; Schedule-H
VERSION
RxIndia v0.1 — 19 Feb 2026
REFERENCES
- CDSCO approved prescribing information
- Indian Pharmacopoeia/National Formulary of India
- AIIMS Drug Formulary
- API Textbook of Medicine
- Indian Ophthalmic Clinical Practice Guidelines
- Standard textbooks of clinical pharmacology (for cross-validation)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.